

# Supplementary Appendix:

## Projecting the impact of SARS-CoV-2 variants on the COVID-19 epidemic and social restoration in the United States: a mathematical modelling study

This supplementary document describes in detail the model construction, calibration, prediction, and estimation of parameters presented in the main text.

### 1. Model construction

#### 1.1 Model structure and formulation

We extended a previously published dynamic compartmental model [1] to describe the circulation of two SARS-CoV-2 strains (the wildtype and B.1.1.7 variant) in the US. The population is divided into eighteen compartments (**Figure S1**), it includes susceptible individuals (S), vaccinated individuals (V), and sixteen compartments in pair infected by wild strains or B.1.1.7 variant. These sixteen compartments are latent infections (E, E<sub>m</sub>), asymptomatic infections (A, A<sub>m</sub>), undiagnosed infections with mild/moderate (I<sub>1</sub>, I<sub>m,1</sub>) and severe/critical symptoms (I<sub>2</sub>, I<sub>m,2</sub>), diagnosed infections with mild/moderate (T<sub>1</sub>, T<sub>m,1</sub>) and severe/critical symptoms (T<sub>2</sub>, T<sub>m,2</sub>), recovered (R, R<sub>m</sub>) and deceased (D, D<sub>m</sub>) cases, respectively. The total population size is denoted by N, where  $N=S+V+E+A+I_1+I_2+T_1+T_2+R+E_m+A_m+I_{m,1}+I_{m,2}+T_{m,1}+T_{m,2}+R_m$ . The model is described by the following system of ordinary differential equations:

$$\begin{cases}
\frac{dS}{dt} = -(\lambda_{pub} + \lambda_{m,pub})(S - S_f) - (\lambda_{pri} + \lambda_{m,pri})S_f - wS, \\
\frac{dV}{dt} = wS - [(1 - \varepsilon_V)\lambda_{pub} + (1 - \varepsilon_{m,V})\lambda_{m,pub}](V - V_f) - [(1 - \varepsilon_V)\lambda_{pri} + (1 - \varepsilon_{m,V})\lambda_{m,pri}]V_f, \\
\frac{dN_f}{dt} = r \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + [(1 - \varepsilon_V)\lambda_{pub} + (1 - \varepsilon_{m,V})\lambda_{m,pub}](V - V_f) \right\} - \xi N_f, \\
\frac{dS_f}{dt} = (r - 1) \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + [(1 - \varepsilon_V)\lambda_{pub} + (1 - \varepsilon_{m,V})\lambda_{m,pub}](V - V_f) \right\} \frac{S_f}{S_f + V_f} - (\lambda_{pri} + \lambda_{m,pri} + \xi)S_f, \\
\frac{dV_f}{dt} = (r - 1) \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + [(1 - \varepsilon_V)\lambda_{pub} + (1 - \varepsilon_{m,V})\lambda_{m,pub}](V - V_f) \right\} \frac{V_f}{S_f + V_f} - (\lambda_{pri}^V + \lambda_{m,pri}^V + \xi)V_f, \\
\frac{dE}{dt} = \lambda_{pub}(S - S_f) + \lambda_{pri}S_f + (1 - \varepsilon_V)\lambda_{pub}(V - V_f) + (1 - \varepsilon_V)\lambda_{pri}V_f - k_1E, \\
\frac{dE_m}{dt} = \lambda_{m,pub}(S - S_f) + \lambda_{m,pri}S_f + (1 - \varepsilon_{m,V})\lambda_{m,pub}(V - V_f) + (1 - \varepsilon_{m,V})\lambda_{m,pri}V_f - k_1E_m, \\
\frac{dA}{dt} = k_1\rho E - \gamma_0A, \\
\frac{dA_m}{dt} = k_1\rho E_m - \gamma_0A_m, \\
\frac{dI_1}{dt} = k_1(1 - \rho)E - \alpha_1I_1 - k_2I_1 - \gamma_0I_1, \\
\frac{dI_{m,1}}{dt} = k_1(1 - \rho)E_m - \alpha_1I_{m,1} - k_2I_{m,1} - \gamma_0I_{m,1}, \\
\frac{dI_2}{dt} = k_2I_1 - \alpha_2I_2 - \mu_1I_2, \\
\frac{dI_{m,2}}{dt} = k_2I_{m,1} - \alpha_2I_{m,2} - (1 + \mu_{up})\mu_1I_{m,2}, \\
\frac{dT_1}{dt} = \alpha_1I_1 - \gamma_1T_1 - k_3T_1, \\
\frac{dT_{m,1}}{dt} = \alpha_1I_{m,1} - \gamma_1T_{m,1} - k_3T_{m,1}, \\
\frac{dT_2}{dt} = \alpha_2I_2 + k_3T_1 - \gamma_2T_2 - \mu_2T_2, \\
\frac{dT_{m,2}}{dt} = \alpha_2I_{m,2} + k_3T_{m,1} - \gamma_2T_{m,2} - (1 + \mu_{up})\mu_2T_{m,2}, \\
\frac{dR}{dt} = \gamma_0A + \gamma_0I_1 + \gamma_1T_1 + \gamma_2T_2, \\
\frac{dR_m}{dt} = \gamma_0A_m + \gamma_0I_{m,1} + \gamma_1T_{m,1} + \gamma_2T_{m,2}, \\
\frac{dD}{dt} = \mu_1I_2 + \mu_2T_2, \\
\frac{dD_m}{dt} = (1 + \mu_{up})\mu_1I_{m,2} + (1 + \mu_{up})\mu_2T_{m,2}.
\end{cases}$$

## 25 **1.2 The disease progression**

26 In our model, the number of residents ( $N$ ) are divided into households members ( $N_f$ ) and public  
27 members ( $N-N_f$ ) to capture varied force of infection in the public settings (e.g. public  
28 transportations, supermarkets, offices, etc) and household (home or other private settings). The  
29 number of households members ( $N_f$ ) are dependent on the number of infected individuals and  
30 their family member ( $r$ ), while the rest of residents denote as public members ( $N-N_f$ ). We assumed  
31 that the number of the households at risk of infection is the same as the number of individuals  
32 infected in public settings because the probability of two or more household members being  
33 infected at the same time but at different public venues is very small. The average number of  
34 household members ( $r$ ) in a US family was estimated as 4 [2] and the mean recovery period  
35 ( $1/\xi$ ) of the infected family members was 28 days [3]. The details values of parameters are list  
36 in the **Table S1**.

37

38 A susceptible or vaccinated individual ( $S, V$ ) may be infected by a SARS-CoV-2 strain (either  
39 the wildtype or B.1.1.7) and entered a latent infection stage ( $E, E_m, m$  denotes variant). Undergo  
40 a mean incubation of 5.2 (4.1-7.0) days, a proportion of infected individuals developed  
41 symptoms ( $I_1, I_{m,1}$ ) before diagnosis and report ( $T_1, T_{m,1}$ ), while the rest infected individuals  
42 ( $A, A_m$ ) would not show any symptoms and move forward to recovery ( $R, R_m$ ). Both  
43 undiagnosed and diagnosed infected individuals could progress to severe/critical stage ( $I_2, I_{m,2},$   
44  $T_2, T_{m,2}$ ) and unalterably occur to death ( $D, D_m$ ) or recovery, but with varied progress rate on  
45 account of medical care.

46

## 47 **1.3 Force of infection**

48 For susceptible individuals ( $S$ ), the infection rates were denoted by the force of infection  
49  $\lambda_{pub}(t), \lambda_{pri}(t), \lambda_{m,pub}(t)$  and  $\lambda_{m,pri}(t)$  as shown in eq. (1), which meant the probability of

50 a susceptible individual infected by wildtype and B.1.1.7 variant in public settings and  
 51 households. The force of infection was dependent on the number of latent, asymptomatic ( $E$ ,  
 52  $E_m$ ,  $A$ ,  $A_m$ ) and undiagnosed symptomatic infections ( $I_1$ ,  $I_{1,m}$ ,  $I_2$ ,  $I_{2,m}$ ). Previous studies had  
 53 reported a 75% lower infectiveness ( $\varepsilon$ ) of latent, asymptomatic individuals ( $E$ ,  $A$ ) compared  
 54 with symptomatic individuals ( $I_1$ ,  $I_2$ ) [4]. For vaccinated individuals ( $V$ ), the force of infection  
 55 was supposed to decline that depends on the vaccine's effectiveness for wildtype ( $\varepsilon_V$ ) or B.1.1.7  
 56 variant ( $\varepsilon_{m,V}$ ) and denoted by  $(1 - \varepsilon_V)\lambda_{pub}(t)$ ,  $(1 - \varepsilon_V)\lambda_{pri}(t)$ ,  $(1 - \varepsilon_{m,V})\lambda_{m,pub}(t)$  and  
 57  $(1 - \varepsilon_{m,V})\lambda_{m,pri}(t)$ .

$$\begin{aligned}
 \lambda_{pub}(t) &= [(1 - \varepsilon)(E + A) + (I_1 + I_2)]\beta_{pub}(t)\frac{1}{N - N_f}, \\
 \lambda_{pri}(t) &= [(1 - \varepsilon)(E + A) + (I_1 + I_2)]\beta_{pri}(t)\frac{1}{N_f}, \\
 \lambda_{m,pub}(t) &= [(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2})](1 + \beta_{up})\beta_{pub}(t)\frac{1}{N - N_f}, \\
 \lambda_{m,pri}(t) &= [(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2})](1 + \beta_{up})\beta_{pri}(t)\frac{1}{N_f}.
 \end{aligned}
 \tag{1}$$

59 Where

$$\begin{aligned}
 \beta_{pub}(t) &= \beta m_{pub}(t)(1 - \theta_1 p_{pub}(t))(1 - \theta_2 q(t)), \\
 \beta_{pri}(t) &= \beta m_{pri}(t)(1 - \theta_2 q(t)),
 \end{aligned}
 \tag{2}$$

61 The force of infection also depends on the effective contacts rate ( $\beta_{pub}$ ,  $\beta_{pri}$ ) in the population,  
 62 which are the product of contact number ( $m_{pub}$ ,  $m_{pri}$ ) and transmission probability of per-  
 63 contact with wildtype ( $\beta$ ) or B.1.1.7 variant ( $\beta_m$ ) infections. Previous literature has reported a  
 64 59% (56-63%) higher transmissibility in B.1.1.7 ( $\beta_m$ ) compared with the wildtype ( $\beta$ ) [5].

65

66 To simulate the community strategies for COVID-19 epidemic, we considered three non-  
 67 pharmaceutical interventions (NPIs, i.e., restricting social distancing, insisting mask use, and  
 68 keeping hand hygiene) to control the force of infection and further reduce infections and deaths.

69 Restricting social distancing in different epidemic stages would reduce the public contact  
70 number ( $m_{pub}$ ) but inversely increase the household contact number ( $m_{pri}$ ). Using masks  
71 could lower per-contact transmission probability ( $\beta, \beta_m$ ) in public settings that lie with the  
72 usage percentage and effectiveness of the masking in preventing infection. Washing hands with  
73 soap and water whenever possible are also considered to prevent the spread of COVID-19  
74 because it reduces the amount of virus on hands, which means to reduce per-contact  
75 transmission probability ( $\beta, \beta_m$ ) in both public settings and household, too. In our model, the  
76 effectiveness of masking and handwashing in preventing infection were 85% (95% CI: 66-  
77 93%) and 42% (50-95%), respectively [6, 7]. Based on the trend of social interventions of  
78 public surveys [8, 9], we assumed that the three NPIs as well as the vaccination rate ( $w$ ) change  
79 in different epidemic stages following Logistic function as follow.

$$80 \quad y(t) = y_{ini} + \frac{y_{end} - y_{ini}}{1 + e^{-k(t-t_{mid})}} \quad (3)$$

81 Logistic function is a common S-shaped function, the initial stage is roughly exponential  
82 growth or reduction; and then it slows down as it starts to saturate; finally, the increase stops  
83 when it reaches maturity. Logistic function is dependent on four parameters: (1) the initial value  
84 of growth or reduction  $y_{ini}$ ; (2) the end value of growth or reduction  $y_{end}$ ; (3) the rate of  
85 exponential growth or reduction  $k$ ; (4) the time when appearance of mid value in growth or  
86 reduction  $t_{mid}$ . The details of Logistic function are list in the **Table S2**.

87

## 88 **2. Model calibration**

89

### 90 **2.1 Data sources**

91 We collected publicly available reportable epidemiological data in the US from Johns Hopkins  
92 University Coronavirus Resource Center [10] and the Centers for Disease Control and

93 Prevention (CDC) [11, 12]. These websites provided daily confirmed COVID-19 infection  
94 cases and death cases from 1st March 2020 to 31st May 2021, the number of COVID-19  
95 vaccination uptakes and variant proportions from 13th December 2020 to 8th May 2021. All  
96 four types of data were used to calibrate the model. An additional table file shows this in more  
97 detail [see **Additional file 1**]

98

## 99 **2.2 Model calibration**

100 We calibrated the model by fitting the daily COVID-19 infections, deaths, vaccination, and  
101 proportion of variants in the US from 1<sup>st</sup> March 2020 to 31<sup>st</sup> May 2021, and predicted the daily  
102 and cumulative infections and deaths of COVID-19 over the next 12 months (from 1<sup>st</sup> June  
103 2021 to 31<sup>st</sup> May 2022). We used the nonlinear least-squares method to minimise the Root  
104 Mean Squared Error (RMSE) between four types of model-simulated and reported data. Due  
105 to the varied orders of magnitude of four data, we standardised these data for the same orders  
106 of magnitude by dividing by the max value of the datasets, which could avoid the fitting process  
107 automatically skewing larger orders of magnitude data and better match each type of data  
108 (Figure 1). We estimated some of the model parameters by data fitting and obtained the other  
109 model parameters from the published literatures (**Table S1**).

110

111 Based on the 'calibrated' scenario, we perturbed model parameters around the 'calibrated'  
112 parameter set to generate a band of curves that best describe the data variations and retain a  
113 minimal level of RMSE. We randomly generated 200 small 'perturbing factors'. For each of  
114 the perturbing factors, we randomly sampled 100 parameter sets based on Latin Hypercube  
115 Sampling (LHS) between the parameter range generated by a random walk (adding the  
116 perturbing factor in both positive and negative directions). Hence, we obtained 200 groups of  
117 various perturbation, and each group has 100 randomised parameter sets. For each of the 200

118 groups, we calculated the number of data points covered by the band of curves simulated by  
119 the 100 parameter sets and their RMSE. We hence selected the one with the minimal RMSE  
120 across 200 bands as the set of simulations that best explained the observed data. The 100 curves  
121 in the selected band were used to calculate the 95% CI of the model outcomes. The vaccine  
122 effectiveness against B.1.1.7 was estimated spontaneously during model calibration. We  
123 validated that the estimated effectiveness of 88.5% produced the lowest RMSE in Figure S2.

124

### 125 **2.3 Model validation for estimated vaccines effectiveness on B.1.1.7 variant**

126 To estimate current vaccines effectiveness on B.1.1.7 variant, we conducted the separate  
127 compartments for wildtype and B.1.1.7 to dynamically simulate total infections and deaths  
128 under the vaccine protection, which were calibrated by daily reported COVID-19 infection  
129 cases and death cases. With the known vaccine effectiveness on wildtype and its proportion of  
130 new infections, we calculated the infections and deaths caused by B.1.1.7 from total and further  
131 estimated the vaccine effectiveness on B.1.1.7.

132

133 The estimate is dependent on the model calibration and parameters optimization. To validate  
134 the reliability of estimated vaccine effectiveness, we conducted an extra comparison of the total  
135 variance (the sum of square errors of four types of data) in 0-100% vaccine effectiveness on  
136 B.1.1.7 variant (**Figure S2**). The minimum of total variance means the best match of  
137 simulations and actual epidemic data, at this point the estimated vaccine effectiveness was the  
138 best suit for available epidemic data.

139

## 140 **3. Model prediction**

141

### 142 **3.1 Construction of scenarios**

143 The emergence of E484K substitution in B.1.1.7 or other new variants may potentially reduce  
144 the effectiveness of the existing vaccines. We evaluate its impact on the COVID-19 epidemic  
145 when the vaccine effectiveness (1) adopts the model-estimated value for B.1.1.7 (baseline  
146 scenario); reduces to (2) 75%; (3) 50% and (4) 25%. For each scenario, we calculated the  
147 cumulative infections and deaths due to COVID-19 over the next 12 months (1<sup>st</sup> June 2021 to  
148 31<sup>st</sup> May 2022). Since we did not know the viral properties of potential new variants, we also  
149 simulated nine scenarios with varying viral transmissibility and mortality as a sensitivity  
150 analysis (Figure 2).

151

### 152 **3.2 Impact of social restoration**

153 Social restoration means releasing restrictions of daily shopping, working, meeting or  
154 gathering, and traveling, which would significantly enlarge the force of infection for both wild  
155 type and B.1.1.7 variant. To assess the timing of social restoration and herd immunity, we  
156 conducted three situations of social restoration at 60%, 65%, and 70% vaccination coverage  
157 levels and calculated the cumulative infections and deaths of COVID-19 over the next 12  
158 months to evaluate their impact on the COVID-19 epidemic trend (Figure 3).

159

### 160 **3.3 Uncertainty and sensitivity analyses**

161 Based on the selected 100 parameter sets in model calibration, we produced the sensitivity  
162 analysis to accommodate the uncertainty of model parameters and determine the 95% CI of the  
163 cumulative COVID-19 infections and deaths. In addition, we also explore the impact on the  
164 epidemic trends of COVID-19 in several scenarios (new variants emerge with higher  
165 transmissibility, mortality, and lower vaccine effectiveness; social restoration; Figures 2-3).  
166 All analyses and simulations were performed in MATLAB R 2019b.

167



**Table S1.** The values of parameters based on references or estimation by nonlinear least-squares (NLS) method in the US.

Parameter	Description	Range or 95% CI from NLS	Source
$1/k_1$	The mean incubation time (days)	5.2 (4.1-7.0)	[13]
$1/k_2$	The mean time from undiagnosed mild/moderate stage to undiagnosed severe/critical stage (days)	10	[14]
$k_3$	The progression rate from diagnosed mild/moderate stage to diagnosed severe/critical stage	$0.0287 (0.0284-0.0291) \times k_2$	NLS
$1/\alpha_1(t)$	The average period from symptoms onset to diagnose for mild/moderate cases (days)	Decreased by logistic function: Mar 1, 2020-May 31, 2022: 7.74 (7.65-7.82)-3.29 (3.25-3.33)	NLS
$1/\alpha_2$	The average diagnose period for severe/critical cases (days)	2.23 (2.20-2.25)	NLS
$1/\gamma_0$	The mean time for natural recovery (days)	10.65 (10.53-10.78)	NLS
$1/\gamma_1$	The average recovery period for diagnosed mild/moderate cases (days)	7	[15, 16]
$1/\gamma_2$	The average recovery period for diagnosed severe/critical cases (days)	$21 - 1/\alpha_2$	[16]
$r$	The mean number of members in a family	4	[2]
$1/\xi$	The mean recovery period for infected family members (days)	28	[3]
$E(0)$	The initial value of latent individuals infected by widetype	190 (188-192)	NLS
$E_m(0)$	The initial value of latent individuals infected by B.1.1.7	62548 (61813-63282)	NLS
$A(0)$	The initial value of asymptomatic individuals infected by widetype	190 (188-192)	NLS
$I_1(0)$	The initial value of undiagnosed mild/moderate cases infected by widetype	190 (188-192)	NLS
$I_2(0)$	The initial value of undiagnosed severe/critical cases infected by widetype	190 (188-192)	NLS
$\beta$	The per-act transmission probability in contact with infected individuals with symptoms by widetype	0.0303 (0.0299-0.0306)	NLS
$\beta_m$	The per-act transmission probability in contact with infected individuals with symptoms caused by B.1.1.7	$59\% (56-63\%) \times \beta + \beta$	NLS and literatures [5]
$\varepsilon$	The reduction in per-act transmission probability if infection is in latent and asymptomatic stage	75%	[4]

Parameter	Description	Range or 95% CI from NLS	Source
$\rho$	The probability that an individual is asymptomatic	0.4964 (0.4904-0.5023)	NLS
$\varepsilon_V$	The weighted effectiveness of vaccines (Pfizer, Moderna and J&J Jensen)	91.4% (92.6%, 92.1%, 66.9%)	[17-19]
$\varepsilon_{m,V}$	The effectiveness of vaccines for B.1.1.7	88.5% (87.4-89.5%)	NLS
$\theta_1$	The effectiveness of mask in preventing infection	0.85 (0.66-0.93)	[6]
$\theta_2$	The effectiveness of handwashing in preventing infection	0.42 (0.1-0.95)	[7]
$\mu_1(t)$	Disease-induced death rate of undiagnosed severe/critical cases infected by witype	Decreased by logistic function: Mar 1, 2020-May 31, 2022: 0.0527 (0.0521-0.0533)-0.0224 (0.0222- 0.0226)	NLS
$\mu_2(t)$	Disease-induced death rate of diagnosed severe/critical cases infected by witype	0.0358 (0.0354-0.0363) $\times \mu_1(t)$	NLS
$\mu_{m,1}(t)$	Disease-induced death rate of undiagnosed severe/critical cases infected by B.1.1.7	45% (18-78%) $\times \mu_1(t) + \mu_1(t)$	NLS and literatures [20]
$\mu_{m,2}(t)$	Disease-induced death rate of diagnosed severe/critical cases infected by B.1.1.7	0.0358 (0.0354-0.0363) $\times \mu_{m,1}(t)$	NLS and literatures [20]
$m_{pub,ini}$	Base daily contact number in the public settings	34.81 (34.41-35.20)	NLS
$m_{pri,ini}$	Base daily contact number in the households	4	[21]
$m_{pub}(t)$	The percentage of base daily contact number in the public settings	Shown in the Table S2	NLS and literatures [8, 9]
$m_{pri}(t)$	The percentage of base daily contact number in the households	Shown in the Table S2	NLS and literatures [8, 9]
$p_1(t)$	The usage percentage of face mask in the public settings	Shown in the Table S2	NLS and literatures [8]
$q(t)$	The usage percentage of handwashing	Shown in the Table S2	NLS and literatures [22, 23]
$w(t)$	The vaccination rate for susceptible individuals (per day)	Shown in the Table S2	NLS


169

170

171 **Table S2.** The details of Logistic function based on trend of social interventions of public surveys or estimation by nonlinear least-squares (NLS)  
 172 method.


parameters	Mar 1 2020- Jun 4, 2020	Mar 1 2020- Sep 5, 2020	Mar 1, 2020- Mar 31, 2022	Jun 5 2020- Sep 5 2020	Sep 6 2020- Dec 17, 2020	Dec 18 2020- Mar 3, 2021	Mar 4, 2021- Apr 2, 2021	Apr 3, 2021- May31, 2022	
$m_{pub}(t)$	Initial	100.00%	—	—	16.8%	45.2%	66.8%	62.5%	83.5%
	end value	16.8%	—	—	45.2%	66.8%	62.5%	83.5%	67.3%
	rate	0.2159	—	—	0.2159	0.1699	0.1699	0.2159	0.2159
	mid-point	Api 2, 2020	—	—	Jun 4, 2020	Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
$m_{pri}(t)$	Initial	100.00%	—	—	200.00%	165.9%	139.9%	145.1%	119.9%
	end value	200.00%	—	—	165.9%	139.9%	145.1%	119.9%	139.3%
	rate	0.2159	—	—	0.2159	0.1699	0.1699	0.2159	0.2159
	mid-point	Api 2, 2020	—	—	Jun 4, 2020	Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
$p_{pub}(t)$	Initial	—	0.00%	—	—	51.4%	45.9%	64.3%	46.9%
	end value	—	51.4%	—	—	45.9%	64.3%	46.9%	62.4%
	rate	—	0.2159	—	—	0.1699	0.1699	0.2159	0.2159
	mid-point	—	Jul 12, 2020	—	—	Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
$q(t)$	Initial	—	—	77%	—	—	—	—	—
	end value	—	—	95%	—	—	—	—	—
	rate	—	—	0.2159	—	—	—	—	—
	mid-point	—	—	Api 2, 2020	—	—	—	—	—
$w(t)$	Initial	—	—	0	—	—	—	—	—
	end value	—	—	0.0188	—	—	—	—	—
	rate	—	—	0.0215	—	—	—	—	—
	mid-point	—	—	Apr 10, 2021	—	—	—	—	—

173



174

175 **Figure S1.** A schematic flow diagram of the transmission of COVID-19 and its mutants.



176

177 **Figure S2.** The validation for estimated vaccine effectiveness on B.1.1.7 variant. The four  
 178 colored line denote the average standardized variance between four types of simulated and  
 179 reported data in 0-100% vaccine effectiveness on B.1.1.7 variant. The arrows point to the  
 180 lowest point of the simulated curve.

181

182 **Supplement Reference**

- 183 1. Shen M, Zu J, Fairley CK, Pagán JA, An L, Du Z, Guo Y, Rong L, Xiao Y, Zhuang G *et al*: **Projected**  
184 **COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine**  
185 **and implications for social distancing and face mask use.** *Vaccine* 2021, **39**(16):2295-2302.
- 186 2. **Average size of households in the U.S. 2019.** Statista.  
187 [<https://www.statista.com/statistics/183648/average-size-of-households-in-the-us/>]
- 188 3. Shen M, Peng Z, Guo Y, Rong L, Li Y, Xiao Y, Zhuang G, Zhang L: **Assessing the effects of**  
189 **metropolitan-wide quarantine on the spread of COVID-19 in public space and households.** *Int J*  
190 *Infect Dis* 2020, **96**:503-505.
- 191 4. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, Jit M, Klepac P: **The effect of control**  
192 **strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a**  
193 **modelling study.** *Lancet Public Health* 2020, **5**(5):e261-e270.
- 194 5. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW,  
195 Tully DC, Washburne AD *et al*: **Estimated transmissibility and impact of SARS-CoV-2 lineage**  
196 **B.1.1.7 in England.** *Science* 2021.
- 197 6. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ: **Physical distancing, face masks, and**  
198 **eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a**  
199 **systematic review and meta-analysis.** *Lancet* 2020, **395**(10242):1973-1987.
- 200 7. Fung IC, Cairncross S: **Effectiveness of handwashing in preventing SARS: a review.** *Trop Med Int*  
201 *Health* 2006, **11**(11):1749-1758.
- 202 8. **Delphi survey results about the spread and impact of the COVID-19 pandemic in the United States**  
203 [<https://delphi.cmu.edu/covidcast/survey-results/?region=9&date=20210511>]
- 204 9. **Understand the impact of COVID-19 using real data** [[https://www.unacast.com/covid19/social-](https://www.unacast.com/covid19/social-distancing-scoreboard)  
205 [distancing-scoreboard](https://www.unacast.com/covid19/social-distancing-scoreboard)]
- 206 10. **Coronavirus Resource Center: COVID-19 Tracking** [<https://coronavirus.jhu.edu>]
- 207 11. **COVID-19 Vaccinations in the United States** [<https://covid.cdc.gov/covid-data-tracker/#vaccinations>]
- 208 12. **Variant Proportions in the US** [<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>]
- 209 13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY *et al*: **Early**  
210 **Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.** *N Engl J*  
211 *Med* 2020, **382**(13):1199-1207.
- 212 14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y *et al*: **Clinical**  
213 **Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in**  
214 **Wuhan, China.** *Jama* 2020, **323**(11):1061-1069.
- 215 15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X *et al*: **Clinical features of**  
216 **patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet* 2020, **395**(10223):497-506.
- 217 16. **Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)**  
218 [[https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))  
219 [disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))]
- 220 17. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N,  
221 Creech CB *et al*: **Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.** *N Engl J Med* 2021,  
222 **384**(5):403-416.
- 223 18. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira  
224 ED, Zerbini C *et al*: **Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.** *N Engl J Med*  
225 2020, **383**(27):2603-2615.
- 226 19. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,  
227 Fennema H, Spiessens B *et al*: **Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against**  
228 **Covid-19.** *N Engl J Med* 2021.
- 229 20. Kow CS, Merchant HA, Hasan SS: **Mortality risk in patients infected with SARS-CoV-2 of the**  
230 **lineage B.1.1.7 in the UK.** *J Infect* 2021.
- 231 21. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS: **Strategies for mitigating an**  
232 **influenza pandemic.** *Nature* 2006, **442**(7101):448-452.
- 233 22. Park CL, Russell BS, Fendrich M, Finkelstein-Fox L, Hutchison M, Becker J: **Americans' COVID-19**  
234 **Stress, Coping, and Adherence to CDC Guidelines.** *J Gen Intern Med* 2020, **35**(8):2296-2303.
- 235 23. Pogrebna G, Kharlamov A: **The Impact of Cross-Cultural Differences in Handwashing Patterns on**  
236 **the COVID-19 Outbreak Magnitude; 2020.**
- 237